Literature DB >> 33617218

Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing.

Adriana Gamboa Lopez, Srinivasa Rao Allu1, Patricia Mendez, Guddeti Chandrashekar Reddy1, Hannah M Maul-Newby, Arun K Ghosh1, Melissa S Jurica.   

Abstract

Small molecules that target the spliceosome SF3B complex are potent inhibitors of cancer cell growth. The compounds affect an early stage of spliceosome assembly when U2 snRNP first engages the branch point sequence of an intron. Employing an inactive herboxidiene analog (iHB) as a competitor, we investigated factors that influence inhibitor interactions with SF3B to interfere with pre-mRNA splicing in vitro. Order-of-addition experiments show that inhibitor interactions are long lasting and affected by both temperature and the presence of ATP. Our data are also consistent with the model that not all SF3B conformations observed in structural studies are conducive to productive inhibitor interactions. Notably, SF3B inhibitors do not impact an ATP-dependent rearrangement in U2 snRNP that exposes the branch binding sequence for base pairing. We also report extended structure-activity relationship analysis of the splicing inhibitor herboxidiene. We identified features of the tetrahydropyran ring that mediate its interactions with SF3B and its ability to interfere with splicing. In the context of recent structures of SF3B bound to inhibitor, our results lead us to extend the model for early spliceosome assembly and inhibitor mechanism. We postulate that interactions between a carboxylic acid substituent of herboxidiene and positively charged SF3B1 side chains in the inhibitor binding channel are needed to maintain inhibitor occupancy while counteracting the SF3B transition to a closed state that is required for stable U2 snRNP interactions with the intron.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33617218      PMCID: PMC8189251          DOI: 10.1021/acschembio.0c00965

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  47 in total

1.  The organization of 3' splice-site sequences in mammalian introns.

Authors:  R Reed
Journal:  Genes Dev       Date:  1989-12       Impact factor: 11.361

2.  Structures of the fully assembled Saccharomyces cerevisiae spliceosome before activation.

Authors:  Rui Bai; Ruixue Wan; Chuangye Yan; Jianlin Lei; Yigong Shi
Journal:  Science       Date:  2018-05-24       Impact factor: 47.728

3.  U2 as well as U1 small nuclear ribonucleoproteins are involved in premessenger RNA splicing.

Authors:  D L Black; B Chabot; J A Steitz
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

Review 4.  Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery.

Authors:  Debanjana Maji; Alan Grossfield; Clara L Kielkopf
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-11-09       Impact factor: 4.490

5.  Scanning from an independently specified branch point defines the 3' splice site of mammalian introns.

Authors:  C W Smith; E B Porro; J G Patton; B Nadal-Ginard
Journal:  Nature       Date:  1989-11-16       Impact factor: 49.962

6.  Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation.

Authors:  Gabriel A Roybal; Melissa S Jurica
Journal:  Nucleic Acids Res       Date:  2010-06-06       Impact factor: 16.971

7.  Recognition of the TACTAAC box during mRNA splicing in yeast involves base pairing to the U2-like snRNA.

Authors:  R Parker; P G Siliciano; C Guthrie
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

8.  Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.

Authors:  Rachel B Darman; Michael Seiler; Anant A Agrawal; Kian H Lim; Shouyong Peng; Daniel Aird; Suzanna L Bailey; Erica B Bhavsar; Betty Chan; Simona Colla; Laura Corson; Jacob Feala; Peter Fekkes; Kana Ichikawa; Gregg F Keaney; Linda Lee; Pavan Kumar; Kaiko Kunii; Crystal MacKenzie; Mark Matijevic; Yoshiharu Mizui; Khin Myint; Eun Sun Park; Xiaoling Puyang; Anand Selvaraj; Michael P Thomas; Jennifer Tsai; John Y Wang; Markus Warmuth; Hui Yang; Ping Zhu; Guillermo Garcia-Manero; Richard R Furman; Lihua Yu; Peter G Smith; Silvia Buonamici
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

9.  Design and synthesis of herboxidiene derivatives that potently inhibit in vitro splicing.

Authors:  Arun K Ghosh; Srinivasa Rao Allu; Guddeti Chandrashekar Reddy; Adriana Gamboa Lopez; Patricia Mendez; Melissa S Jurica
Journal:  Org Biomol Chem       Date:  2021-02-18       Impact factor: 3.876

10.  Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages.

Authors:  Kerstin A Effenberger; Veronica K Urabe; Beth E Prichard; Arun K Ghosh; Melissa S Jurica
Journal:  RNA       Date:  2016-01-07       Impact factor: 4.942

View more
  3 in total

1.  Comprehensive analysis of spliceosome genes and their mutants across 27 cancer types in 9070 patients: clinically relevant outcomes in the context of 3P medicine.

Authors:  Zhen Ye; Aiying Bing; Shulian Zhao; Shuying Yi; Xianquan Zhan
Journal:  EPMA J       Date:  2022-05-10       Impact factor: 8.836

2.  Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression.

Authors:  Mark Sellin; Ryan Mack; Matthew C Rhodes; Lei Zhang; Stephanie Berg; Kanak Joshi; Shanhui Liu; Wei Wei; Peter Breslin S J; Peter Larsen; Richard E Taylor; Jiwang Zhang
Journal:  Br J Cancer       Date:  2022-04-14       Impact factor: 9.075

3.  Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.

Authors:  Angelo Spinello; Jure Borišek; Luca Malcovati; Alessandra Magistrato
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.